L-Arginine and Reduced N-terminal Pro-brain Natriuretic Peptide Level

Doses used in studies

Time to effect

Median: 3 months · IQR 3 months–3 months · Range 3 months–3 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityNo significant difference
No significant differences in side effects were observed between the two groups, indicating that L-arginine is safe for these patients.
from: Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with
side effectsNo significant difference
No significant differences in side effects were observed between the two groups, indicating that L-arginine is safe for these patients.
from: Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with

1 of 1 paper

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial.